LGM
LENZ

Logos Global Management’s LENZ Therapeutics LENZ Stock Holding History

Logos Global Management’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-58,044
Closed -$5.05M – 66
2021
Q4 		$5.05M Sell
58,044
-114,286
-66% -$9.47M 0.52% 42
2021
Q3 		$19.8M Buy
172,330
+19,364
+13% +$2.87M 1.43% 23
2021
Q2 		$32.9M Buy
+152,966
New +$26.6M 2.77% 8

Other funds holding LENZ

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Logos Global Management's LENZ Position: Q1 2022 in Review

Logos Global Management sold out of LENZ Therapeutics (LENZ) in Q1 2022, closing a stake of 58,044 shares — an estimated $5.05M sold.

Logos Global Management first reported a position in LENZ in Q2 2021 and held it in 3 quarters. The position peaked at $32.9M in Q2 2021. 63 funds tracked by Wall St. Rank hold LENZ as of Q1 2022.

  • Logos Global Management reported no remaining LENZ Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Logos Global Management sold 58,044 LENZ Therapeutics shares in Q1 2022, an estimated $5.05M.
  • Logos Global Management first reported a position in LENZ Therapeutics in Q2 2021 and held it in 3 quarters.
  • Logos Global Management's LENZ Therapeutics position peaked at $32.9M in Q2 2021.
  • 63 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2022.

Based on Logos Global Management's 13F filing for Q1 2022, filed 16 May 2022.